Cancer trials first. Could healthy aging follow? EP2 drugs are already in human cancer trials. Our biology lesson explores the earlier aging opportunity: changing this signal in mice’s immune cleanup cells helped preserve memory, muscle and heart function with age. What would make you trust a team to turn it into a medicine?
When I first invested in longevity biotech, I was excited by what might become possible. Sometimes I invested on a written promise without verifying enough. After more than 25 years in business, I knew how much depends on people solving problems. I needed to bring that same judgment to biotech.
If the first experiment or direction disappoints, who is going to solve the issues and get the medicine across the finish line? Your money backs the people making those decisions. A team page can look impressive while leaving that question unanswered.
Get an early look at selected companies working on EP2, and build the judgment to assess the people behind them. See who is pursuing aging research and who is further along in cancer, then use five questions to judge each team’s experience and ability to deliver. Compare your reasoning with mine and learn what to ask before committing money. This is Gate 3 of our 25-gate framework. Start EverLife’s beginner course with 14 days free.
Build Your Longevity Biotech Evaluation Skills
Learn to judge longevity biotech opportunities for yourself, recognize when a promising pitch needs stronger evidence, and focus your research time on what matters.
Explore Membership